Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Profit After Tax (2020 - 2025)

Tarsus Pharmaceuticals has reported Profit After Tax over the past 6 years, most recently at -$8.4 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$8.4 million for Q4 2025, up 63.77% from a year ago — trailing twelve months through Dec 2025 was -$66.4 million (up 42.52% YoY), and the annual figure for FY2025 was -$66.4 million, up 42.52%.
  • Profit After Tax for Q4 2025 was -$8.4 million at Tarsus Pharmaceuticals, up from -$12.6 million in the prior quarter.
  • Over the last five years, Profit After Tax for TARS hit a ceiling of $10.4 million in Q1 2021 and a floor of -$41.9 million in Q4 2023.
  • Median Profit After Tax over the past 5 years was -$21.4 million (2022), compared with a mean of -$19.7 million.
  • Biggest five-year swings in Profit After Tax: soared 630.2% in 2021 and later crashed 447.17% in 2023.
  • Tarsus Pharmaceuticals' Profit After Tax stood at -$14.9 million in 2021, then increased by 8.43% to -$13.6 million in 2022, then tumbled by 208.13% to -$41.9 million in 2023, then soared by 44.84% to -$23.1 million in 2024, then skyrocketed by 63.77% to -$8.4 million in 2025.
  • The last three reported values for Profit After Tax were -$8.4 million (Q4 2025), -$12.6 million (Q3 2025), and -$20.3 million (Q2 2025) per Business Quant data.